Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'GANGLIOSIDE GM2' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 100 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Vukelic, Z; Metelmann, W; Muthing, J; Kos, M; Peter-Katalinic, J
      Anencephaly: Structural characterization of gangliosides in defined brain regions

      BIOLOGICAL CHEMISTRY
    2. Kirkwood, JM; Ibrahim, JG; Sosman, JA; Sondak, VK; Agarwala, SS; Ernstoff, MS; Rao, U
      High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801

      JOURNAL OF CLINICAL ONCOLOGY
    3. Taniguchi, M; Shinoda, Y; Ninomiya, H; Vanier, MT; Ohno, K
      Sites and temporal changes of gangliosides GM1/GM2 storage in the Niemann-Pick disease type C mouse brain

      BRAIN & DEVELOPMENT
    4. Wu, GS; Lu, ZH; Xie, X; Ledeen, R
      Comparison of ganglioside profiles in nuclei and whole cells of NG108-15 and NG-CR72 lines: changes in response to different neuritogenic stimuli

      DEVELOPMENTAL BRAIN RESEARCH
    5. Beccari, T; Balducci, C; Aisa, MC; Della Fazia, MA; Servillo, G; Orlacchio, A
      Promoter characterization and expression of the gene coding for the human GM2 activator protein

      BIOSCIENCE REPORTS
    6. Sandhoff, K
      The G(M2)-gangliosidoses and the elucidation of the beta-hexosaminidase system

      TAY-SACHS DISEASE
    7. Gilewski, T; Ragupathi, G; Bhuta, S; Williams, LJ; Musselli, C; Zhang, XF; Bencsath, KP; Panageas, KS; Chin, J; Hudis, CA; Norton, L; Houghton, AN; Livingston, PO; Danishefsky, SJ
      Immunization of metastatic breast cancer patients with a fully synthetic globe H conjugate: A phase I trial

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    8. Zervas, M; Dobrenis, K; Walkley, SU
      Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations

      JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
    9. Liscum, L
      Niemann-Pick type C mutations cause lipid traffic jam

      TRAFFIC
    10. Gilewski, T; Adluri, S; Ragupathi, G; Zhang, SL; Yao, TJ; Panageas, K; Moynahan, M; Houghton, A; Norton, L; Livingston, PO
      Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21

      CLINICAL CANCER RESEARCH
    11. Chapman, PB; Morrisey, D; Panageas, KS; Williams, L; Lewis, JJ; Israel, RJ; Hamilton, WB; Livingston, PO
      Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine:A trial comparing doses of G(D2)-keyhole limpet hemocyanin

      CLINICAL CANCER RESEARCH
    12. Walkley, SU; Zervas, M; Wiseman, S
      Gangliosides as modulators of dendritogenesis in normal and storage disease-affected pyramidal neurons

      CEREBRAL CORTEX
    13. Hanibuchi, M; Nishioka, Y; Yanagawa, H; Yano, S; Parajuli, P; Bando, M; Sone, S
      Human interferon-gamma enhances expression of ganglioside GM2 on human lung cancer cells and their susceptibility for antiganglioside GM2 monoclonal antibody-dependent cellular cytotoxicity

      ONCOLOGY RESEARCH
    14. Liu, YJ; Wu, YP; Wada, R; Neufeld, EB; Mullin, KA; Howard, AC; Pentchev, PG; Vanier, MT; Suzuki, K; Proia, RL
      Alleviation of neuronal ganglioside storage does not improve the clinical course of the Niemann-Pick C disease mouse

      HUMAN MOLECULAR GENETICS
    15. Tifft, CJ; Proia, RL
      Stemming the tide: glycosphingolipid synthesis inhibitors as therapy for storage diseases

      GLYCOBIOLOGY
    16. O'Hanlon, GM; Veitch, J; Gallardo, E; Illa, I; Chancellor, AM; Willison, HJ
      Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: Clinical and immunopathological studies

      AUTOIMMUNITY
    17. Lake, DF; Huynh, WC; Hersh, EM
      Natural and induced human antibody response to cancer

      CANCER INVESTIGATION
    18. Pitts, JM; Maloney, ME
      Therapeutic advances in melanoma

      DERMATOLOGIC CLINICS
    19. Foon, KA; Lutzky, J; Baral, RN; Yannelli, JR; Hutchins, L; Teitelbaum, A; Kashala, OL; Das, R; Garrison, J; Reisfeld, RA; Bhattacharya-Chatterjee, M
      Clinical and immune responses in advanced melanoma patients immunized withan anti-idiotype antibody mimicking disialoganglioside GD2

      JOURNAL OF CLINICAL ONCOLOGY
    20. Perico, ME; Mezzanzanica, D; Luison, E; Alberti, P; Panza, L; Russo, G; Canevari, S
      Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    21. Livingston, PO; Ragupathi, G; Musselli, C
      Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues

      JOURNAL OF CLINICAL IMMUNOLOGY
    22. Nakamura, K; Tanaka, Y; Fujino, I; Hirayama, N; Shitara, K; Hanai, N
      Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody

      MOLECULAR IMMUNOLOGY
    23. Bierfreund, U; Kolter, T; Sandhoff, K
      Sphingolipid hydrolases and activator proteins

      SPHINGOLIPID METABOLISM AND CELL SIGNALING, PT A
    24. Wang, ZG; Williams, LJ; Zhang, XF; Zatorski, A; Kudryashov, V; Ragupathi, G; Spassova, M; Bornmann, W; Slovin, SF; Scher, HI; Livingston, PO; Lloyd, KO; Danishefsky, SJ
      Polyclonal antibodies from patients immunized with a globe H-keyhole limpet hemocyanin vaccine: Isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    25. Wright, CS; Li, SC; Rastinejad, F
      Crystal structure of human GM2-activator protein with a novel beta-cup topology

      JOURNAL OF MOLECULAR BIOLOGY
    26. Liu, YS; Schweitzer, L; Renehan, WE
      Development of salt-responsive neurons in the nucleus of the solitary tract

      JOURNAL OF COMPARATIVE NEUROLOGY
    27. Walkley, SU; Zervas, M; Siegel, DA; Dobrenis, K
      Gangliosides as modulators of dendritogenesis in storage disease-affected and normal pyramidal neurons

      DEVELOPMENTAL NEUROPSYCHOLOGY
    28. Cox, J; Coulter, A
      Prospects for the development of new vaccine adjuvants

      BIODRUGS
    29. Dickler, MN; Ragupathi, G; Liu, NX; Musselli, C; Martino, DJ; Miller, VA; Kris, MG; Brezicka, FT; Livingston, PO; Grant, SC
      Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer

      CLINICAL CANCER RESEARCH
    30. Mizutani, K; Oka, N; Akiguchi, I; Satoi, H; Kawasaki, T; Kaji, R; Kimura, J
      Enhancement of TNF-alpha production by ganglioside GM2 in human mononuclear cell culture

      NEUROREPORT
    31. Dullenkopf, W; Ritter, G; Fortunato, SR; Old, LJ; Schmidt, RR
      Synthesis of a structurally defined antigen - Immunostimulant combination for use in cancer vaccines

      CHEMISTRY-A EUROPEAN JOURNAL
    32. Raghavan, S; Leshinsky, E; Kolodny, EH
      G(M2)-ganglioside metabolism in situ in mucolipidosis IV fibroblasts

      NEUROCHEMICAL RESEARCH
    33. Cappello, S; Liu, NX; Musselli, C; Brezicka, FT; Livingston, PO; Ragupathi, G
      Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    34. Crawley, AC; Jones, MZ; Bonning, LE; Finnie, JW; Hopwood, JJ
      alpha-mannosidosis in the guinea pig: A new animal model for lysosomal storage disorders

      PEDIATRIC RESEARCH
    35. Slovin, SF; Ragupathi, G; Adluri, S; Ungers, G; Terry, K; Kim, S; Spassova, M; Bornmann, WG; Fazzari, M; Dantis, L; Olkiewicz, K; Lloyd, KO; Livingston, PO; Danishefsky, SJ; Scher, HI
      Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globoH hexasaccharide conjugate in man

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    36. Saito, M; Ito, M; Sugiyama, K
      A specific loss of c-series gangliosides in pancreas streptozotocin-induced diabetic rats

      LIFE SCIENCES
    37. Khalili-Shirazi, A; Gregson, N; Gray, I; Rees, J; Winer, J; Hughes, R
      Antiganglioside antibodies in Guillain-Barre syndrome after a recent cytomegalovirus infection

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    38. Zervas, M; Walkley, SU
      Ferret pyramidal cell dendritogenesis: Changes in morphology and ganglioside expression during cortical development

      JOURNAL OF COMPARATIVE NEUROLOGY
    39. Neufeld, EB; Wastney, M; Patel, S; Suresh, S; Cooney, AM; Dwyer, NK; Roff, CF; Ohno, K; Morris, JA; Carstea, ED; Incardona, JP; Strauss, JF; Vanier, MT; Patterson, MC; Brady, RO; Pentchev, PG; Blanchette-Mackie, EJ
      The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo

      JOURNAL OF BIOLOGICAL CHEMISTRY
    40. Morton, DL; Ollila, DW; Hsueh, EC; Essner, R; Gupta, RK
      Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma

      CA-A CANCER JOURNAL FOR CLINICIANS
    41. Falk, T; Garver, WS; Erickson, RP; Wilson, JM; Yool, AJ
      Expression of Niemann-Pick type C transcript in rodent cerebellum in vivo and in vitro

      BRAIN RESEARCH
    42. OLLILA DW; KELLEY MC; GAMMON G; MORTON DL
      OVERVIEW OF MELANOMA VACCINES - ACTIVE SPECIFIC IMMUNOTHERAPY FOR MELANOMA PATIENTS

      Seminars in surgical oncology
    43. FOON KA; SEN G; HUTCHINS L; KASHALA OL; BARAL R; BANERJEE M; CHAKRABORTY M; GARRISON J; REISFELD RA; BHATTACHARYACHATTERJEE M
      ANTIBODY-RESPONSES IN MELANOMA PATIENTS IMMUNIZED WITH AN ANTIIDIOTYPE ANTIBODY MIMICKING DISIALOGANGLIOSIDE GD2

      Clinical cancer research
    44. FOON KA; SEN G; HUTCHINS L; KASHALA OL; BARAL R; BANERJEE M; CHAKRABORTY M; GARRISON J; REISFELD RA; BHATTACHARYACHATTERJEE M
      ANTIBODY-RESPONSES IN MELANOMA PATIENTS IMMUNIZED WITH AN ANTIIDIOTYPE ANTIBODY MIMICKING DISIALOGANGLIOSIDE GD2

      Clinical cancer research
    45. ZHANG SL; ZHANG HS; REUTER VE; SLOVIN SF; SCHER HI; LIVINGSTON PO
      EXPRESSION OF POTENTIAL TARGET ANTIGENS FOR IMMUNOTHERAPY ON PRIMARY AND METASTATIC PROSTATE CANCERS

      Clinical cancer research
    46. ZHANG SL; ZHANG HS; REUTER VE; SLOVIN SF; SCHER HI; LIVINGSTON PO
      EXPRESSION OF POTENTIAL TARGET ANTIGENS FOR IMMUNOTHERAPY ON PRIMARY AND METASTATIC PROSTATE CANCERS

      Clinical cancer research
    47. KUO CT; BOSTICK PJ; IRIE RF; MORTON DL; CONRAD AJ; HOON DSB
      ASSESSMENT OF MESSENGER-RNA OF BETA-1-]4-N-ACETYLGALACTOSAMINYLTRANSFERASE AS A MOLECULAR MARKER FOR METASTATIC MELANOMAL

      Clinical cancer research
    48. KUO CT; BOSTICK PJ; IRIE RF; MORTON DL; CONRAD AJ; HOON DSB
      ASSESSMENT OF MESSENGER-RNA OF BETA-1-]4-N-ACETYLGALACTOSAMINYLTRANSFERASE AS A MOLECULAR MARKER FOR METASTATIC MELANOMAL

      Clinical cancer research
    49. SHRAYER DP; BOGAARS H; HEARING VJ; WOLF SF; WANEBO HJ
      A NEW MOUSE MODEL OF EXPERIMENTAL MELANOMA FOR VACCINE AND LYMPHOKINETHERAPY

      International journal of oncology
    50. WALKLEY SU
      CELLULAR PATHOLOGY OF LYSOSOMAL STORAGE DISORDERS

      Brain pathology
    51. KIRKWOOD JM
      SYSTEMIC ADJUVANT TREATMENT OF HIGH-RISK MELANOMA - THE ROLE OF INTERFERON-ALPHA-2B AND OTHER IMMUNOTHERAPIES

      European journal of cancer
    52. EGGERMONT AMM
      STRATEGY OF THE EORTC-MCG TRIAL PROGRAM FOR ADJUVANT TREATMENT OF MODERATE-RISK AND HIGH-RISK MELANOMA

      European journal of cancer
    53. LISCUM L; KLANSEK JJ
      NIEMANN-PICK-DISEASE TYPE-C

      Current opinion in lipidology
    54. WOLCHOK JD; LIVINGSTON PO; HOUGHTON AN
      VACCINES AND OTHER ADJUVANT THERAPIES FOR MELANOMA

      Hematology/oncology clinics of North America
    55. SCHWARZ A; FUTERMAN AH
      INHIBITION OF SPHINGOLIPID SYNTHESIS, BUT NOT DEGRADATION, ALTERS THERATE OF DENDRITE GROWTH IN CULTURED HIPPOCAMPAL-NEURONS

      Developmental brain research
    56. YUZIUK JA; BERTONI C; BECCARI T; ORLACCHIO A; WU YY; LI SC; LI YT
      SPECIFICITY OF MOUSE G(M2) ACTIVATOR PROTEIN AND BETA-N-ACETYLHEXOSAMINIDASE-A AND BETA-N-ACETYLHEXOSAMINIDASE-B - SIMILARITIES AND DIFFERENCES WITH THEIR HUMAN COUNTERPARTS IN THE CATABOLISM OF G(M2)

      The Journal of biological chemistry
    57. MAHURAN DJ
      THE GM2 ACTIVATOR PROTEIN, ITS ROLES AS A COFACTOR IN GM2 HYDROLYSIS AND AS A GENERAL GLYCOLIPID TRANSPORT PROTEIN

      Biochimica et biophysica acta, L. Lipids and lipid metabolism
    58. BASU M; DASTGHEIB S; GIRZADAS MA; ODONNELL PH; WESTERVELT CW; LI ZX; INOKUCHI J; BASU S
      HYDROPHOBIC NATURE OF MAMMALIAN CERAMIDE GLYCANASES - PURIFIED FROM RABBIT AND RAT MAMMARY TISSUES

      Acta Biochimica Polonica
    59. SANDHOFF K; KOLTER T
      PROCESSING OF SPHINGOLIPID ACTIVATOR PROTEINS AND THE TOPOLOGY OF LYOSOMAL DIGESTION

      Acta Biochimica Polonica
    60. BASU SS; DASTGHEIB S; GHOSH S; BASU M; KELLY P; BASU S
      PURIFICATION AND CHARACTERIZATION OF AVIAN GLYCOLIPID - BETA-GALACTOSYLTRANSFERASES (GALT-4 AND GALT-3) - CLONING AND EXPRESSION OF TRUNCATED BETA-GALT-4

      Acta Biochimica Polonica
    61. TAKAHASHI T; IRIE RF; NISHINAKA Y; HOON DSB
      707-AP PEPTIDE RECOGNIZED BY HUMAN-ANTIBODY INDUCES HUMAN-LEUKOCYTE ANTIGEN A2-RESTRICTED CYTOTOXIC T-LYMPHOCYTE KILLING OF MELANOMA

      Clinical cancer research
    62. KUHN CA; HANKE CW
      CURRENT STATUS OF MELANOMA VACCINES

      Dermatologic surgery
    63. EGGERMONT AMM
      THE CURRENT EORTC-MELANOMA-COOPERATIVE-GROUP ADJUVANT TRIAL PROGRAM ON MALIGNANT-MELANOMA - PROGNOSIS VERSUS EFFICACY, TOXICITY AND COSTS

      Melanoma research
    64. LIVINGSTON PO; RAGUPATHI G
      CARBOHYDRATE VACCINES THAT INDUCE ANTIBODIES AGAINST CANCER .2. PREVIOUS EXPERIENCE AND FUTURE-PLANS

      Cancer immunology and immunotherapy
    65. LIVINGSTON P; ZHANG SL; ADLURI S; YAO TJ; GRAEBER L; RAGUPATHI G; HELLING F; FLEISHER M
      TUMOR-CELL REACTIVITY MEDIATED BY IGM ANTIBODIES IN SERA FROM MELANOMA PATIENTS VACCINATED WITH GM2 GANGLIOSIDE COVALENTLY-LINKED TO KLH ISINCREASED BY IGG ANTIBODIES

      Cancer immunology and immunotherapy
    66. TODD CW; POZZI LAM; GUARNACCIA JR; BALASUBRAMANIAN M; HENK WG; YOUNGER LE; NEWMAN MJ
      DEVELOPMENT OF AN ADJUVANT ACTIVE NONIONIC BLOCK-COPOLYMER FOR USE INOIL-FREE SUBUNIT VACCINES FORMULATIONS

      Vaccine
    67. SMILJANICGEORGIJEV N; RIGAT B; XIE B; WANG W; MAHURAN DJ
      CHARACTERIZATION OF THE AFFINITY OF THE G(M2) ACTIVATOR PROTEIN FOR GLYCOLIPIDS BY A FLUORESCENCE DEQUENCHING ASSAY

      Biochimica et biophysica acta. Protein structure and molecular enzymology
    68. CONFORTI AM; OLLILA DW; KELLEY MC; GAMMON G; MORTON DL
      UPDATE ON ACTIVE SPECIFIC IMMUNOTHERAPY WITH MELANOMA VACCINES

      Journal of surgical oncology
    69. GLOMBITZA GJ; BECKER E; KAISER HW; SANDHOFF K
      BIOSYNTHESIS, PROCESSING, AND INTRACELLULAR-TRANSPORT OF G(M2) ACTIVATOR PROTEIN IN HUMAN EPIDERMAL-KERATINOCYTES - THE LYSOSOMAL TARGETINGOF THE G(M2) ACTIVATOR IS INDEPENDENT OF A MANNOSE-6-PHOSPHATE SIGNAL

      The Journal of biological chemistry
    70. HAMA Y; LI YT; LI SC
      INTERACTION OF G(M2) ACTIVATOR PROTEIN WITH GLYCOSPHINGOLIPIDS

      The Journal of biological chemistry
    71. SAKURABA H; ITOH K; KUROKI Y; KASE R; SHIMMOTO M; UTSUMI K; OZAWA H; TAI T; HARA A; UYAMA E
      IMMUNOCYTOCHEMICAL DETECTION OF ACCUMULATED SUBSTRATES IN CULTURED FIBROBLASTS FROM PATIENTS WITH THE INFANTILE AND ADULT FORMS OF SANDHOFF-DISEASE

      Clinica chimica acta
    72. TAKAHASHI T; IRIE RF; MORTON DL; HOON DSB
      RECOGNITION OF GP43 TUMOR-ASSOCIATED ANTIGEN PEPTIDE BY BOTH HLA-A2 RESTRICTED CTL LINES AND ANTIBODIES FROM MELANOMA PATIENTS

      Cellular immunology
    73. MARCH PA; THRALL MA; BROWN DE; MITCHELL TW; LOWENTHAL AC; WALKLEY SU
      GABAERGIC NEUROAXONAL DYSTROPHY AND OTHER CYTOPATHOLOGICAL ALTERATIONS IN FELINE NIEMANN-PICK DISEASE TYPE-C

      Acta Neuropathologica
    74. RAGUPATHI G
      CARBOHYDRATE ANTIGENS AS TARGETS FOR ACTIVE SPECIFIC IMMUNOTHERAPY

      Cancer immunology and immunotherapy
    75. BISHOP JAN
      CURRENT IMMUNOTHERAPY FOR MELANOMA

      Cancer surveys
    76. BODEY B; BODEY B; SIEGEL SE; LUCK JV; KAISER HE
      IMMUNOPHENOTYPIC CHARACTERIZATION OF HUMAN PRIMARY AND METASTATIC MELANOMA INFILTRATING LEUKOCYTES

      Anticancer research
    77. ELKASSAS H; KIRKWOOD JM
      ADJUVANT APPLICATION OF INTERFERONS

      Seminars in oncology
    78. MASTRANGELO MJ; MAGUIRE HC; SATO T; NATHAN FE; BERD D
      ACTIVE SPECIFIC IMMUNIZATION IN THE TREATMENT OF PATIENTS WITH MELANOMA

      Seminars in oncology
    79. TAKAYAMA S; LIVINGSTON PO; WONG CH
      SYNTHESIS OF THE MELANOMA-ASSOCIATED GANGLIOSIDE 9-O-ACETYL GD3 THROUGH REGIOSELECTIVE ENZYMATIC ACETYLATION OF GD3 USING SUBTILISIN

      Tetrahedron letters
    80. NAFTZGER C; TAKECHI Y; KOHDA H; HARA I; VIJAYASARADHI S; HOUGHTON AN
      IMMUNE-RESPONSE TO A DIFFERENTIATION ANTIGEN-INDUCED BY ALTERED ANTIGEN - A STUDY OF TUMOR REJECTION AND AUTOIMMUNITY

      Proceedings of the National Academy of Sciences of the United Statesof America
    81. HANESSIAN S; QIU DX; PRABHANJAN H; REDDY GV; LOU BL
      SYNTHESIS OF CLUSTERED D-GALNAC(TN) AND D-GAL-BETA(1-]3)GALNAC(T) ANTIGENIC MOTIFS USING A PENTAERYTHRITOL SCAFFOLD

      Canadian journal of chemistry
    82. YAO TJ; BEGG CB; LIVINGSTON PO
      OPTIMAL SAMPLE-SIZE FOR A SERIES OF PILOT TRIALS OF NEW AGENTS

      Biometrics
    83. LIVINGSTON PO
      AUGMENTING THE IMMUNOGENICITY OF CARBOHYDRATE TUMOR-ANTIGENS

      Seminars in cancer biology
    84. KUWANA T; MULLOCK BM; LUZIO JP
      IDENTIFICATION OF A LYSOSOMAL PROTEIN CAUSING LIPID TRANSFER, USING AFLUORESCENCE ASSAY DESIGNED TO MONITOR MEMBRANE-FUSION BETWEEN RAT-LIVER ENDOSOMES AND LYSOSOMES

      Biochemical journal
    85. LIVINGSTON PO
      APPROACHES TO AUGMENTING THE IMMUNOGENICITY OF MELANOMA GANGLIOSIDES - FROM WHOLE MELANOMA-CELLS TO GANGLIOSIDE-KLH CONJUGATE VACCINES

      Immunological reviews
    86. RITTER G; RITTERBOOSFELD E; ADLURI R; CALVES M; REN SL; YU RK; OETTGEN HF; OLD LJ; LIVINGSTON PO
      ANALYSIS OF THE ANTIBODY-RESPONSE TO IMMUNIZATION WITH PURIFIED O-ACETYL GD3 GANGLIOSIDES IN PATIENTS WITH MALIGNANT-MELANOMA

      International journal of cancer
    87. HELLING F; ZHANG S; SHANG A; ADLURI S; CALVES M; KOGANTY R; LONGENECKER BM; YAO TJ; OETTGEN HF; LIVINGSTON PO
      G(M2)-KLH CONJUGATE VACCINE - INCREASED IMMUNOGENICITY IN MELANOMA PATIENTS AFTER ADMINISTRATION WITH IMMUNOLOGICAL ADJUVANT QS-21

      Cancer research
    88. HELLING F; LIVINGSTON PO
      GANGLIOSIDE CONJUGATE VACCINES - IMMUNOTHERAPY AGAINST TUMORS OF NEUROECTODERMAL ORIGIN

      Molecular and chemical neuropathology
    89. SHRAYER D; KONESS J; KOUTTAB N; BOGAARS H; HEARING VJ; MAIZEL A; WANEBO HJ
      ANTITUMOR EFFECTS OF POLYVALENT AND MONOVALENT VACCINES COUPLED WITH INTERLEUKIN-2 IN A METASTATIC MELANOMA MODEL

      International journal of oncology
    90. KOTANI M; HOSOYA H; KUBO H; ITOH K; SAKURABA H; KUSUBATA M; INAGAKI M; YAZAKI K; SUZUKI Y; TAI T
      EVIDENCE FOR DIRECT BINDING OF INTRACELLULARLY DISTRIBUTED GANGLIOSIDE GM2 TO ISOLATED VIMENTIN INTERMEDIATE FILAMENTS IN NORMAL AND TAY-SACHS-DISEASE HUMAN FIBROBLASTS

      Cell structure and function
    91. NOVAK A; CALLAHAN JW; LOWDEN JA
      CLASSIFICATION OF DISORDERS OF G(M2) GANGLIOSIDE HYDROLYSIS USING H-3G(M2) AS SUBSTRATE

      Biochimica et biophysica acta (G). General subjects
    92. SIEGEL DA; WALKLEY SU
      GROWTH OF ECTOPIC DENDRITES ON CORTICAL PYRAMIDAL NEURONS IN NEURONALSTORAGE DISEASES CORRELATES WITH ABNORMAL ACCUMULATION OF GM2 GANGLIOSIDE

      Journal of neurochemistry
    93. HELLING F; SHANG A; CALVES M; ZHANG SL; REN SL; YU RK; OETTGEN HF; LIVINGSTON PO
      G(D3) VACCINES FOR MELANOMA - SUPERIOR IMMUNOGENICITY OF KEYHOLE LIMPET HEMOCYANIN CONJUGATE VACCINES

      Cancer research
    94. BECCARI T; PALMERINI CA; SERVILLO G; DELLAFAZIA MA; MAGNI MPV; ORLACCHIO A
      G(M2) ACTIVATOR PROTEIN EXPRESSION IN MOUSE-TISSUES

      Biochemical and biophysical research communications
    95. BECCARI T; PALMERINI CA; SERVILLO G; DELLAFAZIA MA; MAGNI MPV; ORLACCHIO A
      G(M2) ACTIVATOR PROTEIN EXPRESSION IN MOUSE-TISSUES

      Biochemical and biophysical research communications
    96. TOYOKUNI T; DEAN B; CAI SP; BOIVIN D; HAKOMORI S; SINGHAL AK
      SYNTHETIC VACCINES - SYNTHESIS OF A DIMERIC TN ANTIGEN-LIPOPEPTIDE CONJUGATE THAT ELICITS IMMUNE-RESPONSES AGAINST TN-EXPRESSING GLYCOPROTEINS

      Journal of the American Chemical Society
    97. GLINSKY GV
      GLYCODETERMINANTS OF MELANOMA CELL-ADHESION - A MODEL FOR ANTIMETASTATIC DRUGS DESIGN

      Critical reviews in oncology/hematology
    98. BELLACHIOMA G; STIRLING JL; ORLACCHIO A; BECCARI T
      CLONING AND SEQUENCE-ANALYSIS OF A CDNA CLONE CODING FOR THE MOUSE G(M2) ACTIVATOR PROTEIN

      Biochemical journal
    99. KLIMA H; KLEIN A; VANECHTEN G; SCHWARZMANN G; SUZUKI K; SANDHOFF K
      OVER-EXPRESSION OF A FUNCTIONALLY ACTIVE HUMAN G(M2)-ACTIVATOR PROTEIN IN ESCHERICHIA-COLI

      Biochemical journal
    100. LIVINGSTON PO; CALVES MJ; HELLING F; ZOLLINGER WD; BLAKE MS; LOWELL GH
      GD3 PROTEOSOME VACCINES INDUCE CONSISTENT IGM ANTIBODIES AGAINST THE GANGLIOSIDE GD3/

      Vaccine


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/08/20 alle ore 23:52:29